Creative Medical Technology (NASDAQ:CELZ) Posts Earnings Results, Misses Estimates By $0.49 EPS

Creative Medical Technology (NASDAQ:CELZ) released its quarterly earnings data on Friday. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.49), Zacks reports.

Creative Medical Technology Trading Up 9.0 %

NASDAQ CELZ traded up $0.27 during trading hours on Friday, hitting $3.27. The company’s stock had a trading volume of 155,245 shares, compared to its average volume of 37,240. Creative Medical Technology has a 52 week low of $1.96 and a 52 week high of $6.90. The company has a market capitalization of $7.60 million, a PE ratio of -0.86 and a beta of 1.70. The company’s 50-day simple moving average is $3.69 and its two-hundred day simple moving average is $3.28.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.